Milnacipran

Serotonin and Norepinephrine Reuptake Inhibitor — NERVOUS SYSTEM

Key facts

Milnacipran is an ofp drug in the Serotonin and Norepinephrine Reuptake Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as Norepinephrine Uptake Inhibitors and Serotonin Uptake Inhibitors. DrugCentral lists 7 molecular targets, including SLC6A2, NET and Slc6a4. Recorded indications include Fibromyalgia.

• Approval status: ofp (first approved 2009 by the FDA).
• Drug class: Serotonin and Norepinephrine Reuptake Inhibitor.
• Mechanism of action: Norepinephrine Uptake Inhibitors; Serotonin Uptake Inhibitors.
• Molecular targets: SLC6A2, NET, Slc6a4 and SLC6A4 (7 listed in DrugCentral).
• Indications: Fibromyalgia.
• ATC code: N06AX17 (Other antidepressants).
• Molecular formula: C15H22N2O; molecular weight 246.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Fibromyalgia

Contraindications (17)

• Acute nephropathy
• Alcoholism
• Angle-closure glaucoma
• Blood coagulation disorder
• Disease of liver
• Disorder of cardiovascular system
• Hypertensive disorder
• Hypomania
• Hyponatremia
• Liver function tests abnormal
• Mania
• Seizure disorder
• Serotonin syndrome
• Suicidal
• Syndrome of inappropriate vasopressin secretion
• Tachyarrhythmia
• Urinary tract obstruction

Mechanism & targets

• Mechanism of action (MoA): Norepinephrine Uptake Inhibitors; Serotonin Uptake Inhibitors
• Established pharmacologic class: Serotonin and Norepinephrine Reuptake Inhibitor

Molecular targets (7)

Target	Gene	Action	Activity
Sodium-dependent noradrenaline transporter	SLC6A2	inhibitor	Ki 7.60
Transporter	NET	unknown	IC50 7.52
Sodium-dependent serotonin transporter	Slc6a4	unknown	IC50 7.33
Sodium-dependent serotonin transporter	SLC6A4	inhibitor	Ki 7.29
Sodium-dependent dopamine transporter	SLC6A3	unknown	IC50 5.21
Glutamate receptor ionotropic, NMDA 2A	GRIN2A	unknown	IC50 5.20
Sodium-dependent dopamine transporter	Slc6a3	unknown	IC50 4.43

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2009-01-14	FDA	—	CYPRESS BIOSCIENCE

ATC classification

ATC code	Therapeutic hierarchy
N06AX17	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Suicidal ideation	175.1
Drug hypersensitivity	127.7
Migraine	98.2
Blepharospasm	93.9
Serotonin syndrome	85.2
Somatic delusion	81.5
Taste disorder	79.7
Memory impairment	74.3
Nausea	71.3
Hyperhidrosis	65.9
Epilepsy	59.9
Headache	56.9

Chemical structure

• Molecular formula: C₁₅H₂₂N₂O
• Molecular weight: 246.35 g/mol
• CAS number: 92623-85-3
• InChIKey: GJJFMKBJSRMPLA-UHFFFAOYSA-N
• PubChem CID: 65833

CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Milnacipran used for?

DrugCentral lists the following indications for Milnacipran: Fibromyalgia.

How does Milnacipran work?

Milnacipran is classified as Norepinephrine Uptake Inhibitors and Serotonin Uptake Inhibitors; its molecular targets in DrugCentral include SLC6A2 (inhibitor), NET, Slc6a4 and SLC6A4 (inhibitor).

When was Milnacipran first approved?

Milnacipran was first approved by the FDA in 2009.

What drug class does Milnacipran belong to?

Milnacipran is in the Serotonin and Norepinephrine Reuptake Inhibitor class.

What is the chemical formula of Milnacipran?

Milnacipran has the molecular formula C15H22N2O and a molecular weight of 246.35 g/mol.

Sources

• DrugCentral drug card 1808 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL252923 — compound record and bioactivity
• PubChem CID 65833 — chemical identifiers
• DrugBank DB04896 — drug record
• FDA UNII G56VK1HF36 — substance identity
• DailyMed: FDA labels for Milnacipran — current prescribing information (label search)
• UniProt P23975 (SLC6A2) — target protein
• UniProt P31645 (SLC6A4) — target protein
• UniProt Q01959 (SLC6A3) — target protein
• UniProt Q12879 (GRIN2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.